142 related articles for article (PubMed ID: 36794010)
21. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
22. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
23. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
24. βArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer.
Purayil HT; Daaka Y
Prostate; 2022 May; 82(7):816-825. PubMed ID: 35226379
[TBL] [Abstract][Full Text] [Related]
25. Activin A stimulates AKR1C3 expression and growth in human prostate cancer.
Hofland J; van Weerden WM; Steenbergen J; Dits NF; Jenster G; de Jong FH
Endocrinology; 2012 Dec; 153(12):5726-34. PubMed ID: 23024260
[TBL] [Abstract][Full Text] [Related]
26. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
Fahrenholtz CD; Beltran PJ; Burnstein KL
Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
[TBL] [Abstract][Full Text] [Related]
27. A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Meng F; Li WF; Jung D; Wang CC; Qi T; Shia CS; Hsu RY; Hsieh YC; Duan J
Am J Cancer Res; 2021; 11(7):3645-3659. PubMed ID: 34354865
[TBL] [Abstract][Full Text] [Related]
28. S100A3 suppression inhibits in vitro and in vivo tumor growth and invasion of human castration-resistant prostate cancer cells.
Kang M; Lee HS; Lee YJ; Choi WS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Urology; 2015 Jan; 85(1):273.e9-15. PubMed ID: 25440760
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
30. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Morsy A; Trippier PC
ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
[TBL] [Abstract][Full Text] [Related]
32. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
33. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
[TBL] [Abstract][Full Text] [Related]
34. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
35. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
Hertzog JR; Zhang Z; Bignan G; Connolly PJ; Heindl JE; Janetopoulos CJ; Rupnow BA; McDevitt TM
Prostate; 2020 Oct; 80(14):1223-1232. PubMed ID: 33258507
[TBL] [Abstract][Full Text] [Related]
36. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
37. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
38. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
Wang B; Wu S; Fang Y; Sun G; He D; Hsieh JT; Wang X; Zeng H; Wu K
J Cell Mol Med; 2020 Oct; 24(20):12032-12043. PubMed ID: 32902124
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients.
Swami S; Krishnan AV; Moreno J; Bhattacharyya RS; Gardner C; Brooks JD; Peehl DM; Feldman D
Int J Cancer; 2009 May; 124(9):2050-9. PubMed ID: 19127598
[TBL] [Abstract][Full Text] [Related]
40. DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling.
Gu Y; Wu S; Chong Y; Guan B; Li L; He D; Wang X; Wang B; Wu K
Cell Signal; 2022 Jul; 95():110336. PubMed ID: 35452821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
